Storyline · Since October 22, 2026 · 19 articles
Moderna Merck Melanoma Vaccine Trial
From “Moderna-Merck Vaccine Cuts Melanoma Recurrence” to “Moderna Vaccine Shows Phase 3 Benefit”.
42%
Left · 8
37%
Center · 7
21%
Right · 4
Pano rates the last 30 days Leans Left.
Day by day
Articles a dayOct 22 · 14 articlesModerna-Merck Vaccine Cuts Melanoma Recurrence
Oct 10Nov 8
Chapters
2 chaptersOct 23
Moderna Vaccine Shows Phase 3 Benefit
Moderna and Merck said their personalized mRNA vaccine intismeran, added to Keytruda, cut the two-year risk of melanoma recurrence or death by 42% versus Keytruda alone.
Balanced· 10 articlesOct 22
Moderna-Merck Vaccine Cuts Melanoma Recurrence
Moderna and Merck released detailed results from their late-stage melanoma vaccine trial earlier than planned after the data leaked.
Balanced· 14 articles
